Seeking Alpha

The FDA has approved an application by Merck (MRK +0.7%) to switch the status of the...

The FDA has approved an application by Merck (MRK +0.7%) to switch the status of the prescription patch Oxytrol, a treatment for overactive-bladder, to an over-the-counter item for women. The OTC patch, which will remain a prescription-only product for men, will be available this fall.
Comments (1)
  • berloe
    , contributor
    Comments (1765) | Send Message
     
    Wait a minute! If it's OTC why can't men buy it?
    25 Jan 2013, 05:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs